A Current Review of Targeted Therapeutics for Ovarian Cancer

<table class="table-group" id="tab3"><tr><td><table class="table"><tr><td class="thead-hr" colspan="3"><hr/></td></tr><tr class="thead"><td align="left">Clinical trial.gov ID</td><td align="center">Therapeutic regimen</td><td align="center">Study PI</td></tr><tr><td class="thead-hr" colspan="3"><hr/></td></tr><tr><td align="left">NCT00722592</td><td align="center">Doxil and EC145in platinum resistant EOC</td><td align="center">R. Messmann</td></tr><tr><td align="left">NCT00738699</td><td align="center">MORAb-003 in first platinum resistant or refractory relapsed EOC</td><td align="center">D. Chakraborty</td></tr><tr><td align="left">NCT00849667</td><td align="center">MORAb-003 in platinum sensitive, first relapse EOC</td><td align="center">D. Chakraborty</td></tr><tr class="table-tr"><td colspan="3"><hr class="tbody-hr"/></td></tr></table></td></tr></table>

<i>α</i>-folate receptor inhibitors and ovarian cancer.

Journal of Oncology

tab3

Table 3

Table 3: A Current Review of Targeted Therapeutics for Ovarian Cancer 